Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, Mexico

By Whittington D.   Matsui-Santana O.   Freiberger J.J.   Van Houtven G.   Pattanayak S.  

Vaccine, Vol. 20, Iss. 19, 2002-06 ,pp. : 2585-2591

Elsevier

Access to resources Recommend Favorite

Overview: practical insights from comparative immunology and pathogenesis of AIDS, hepatitis B, and measles for developing an HIV vaccine

By Hilleman M.R.  

Vaccine, Vol. 13, Iss. 18, 1995-01 ,pp. : 1733-1740

Elsevier

Access to resources Recommend Favorite

Molecular basis of the inefficacy and possible harmful effects of AIDS vaccine candidates based on HIV-1 envelope glycoprotein gp120

By Veljkovic V.   Johnson E.   Metlas R.  

Vaccine, Vol. 15, Iss. 5, 1997-04 ,pp. : 473-474

Elsevier

Access to resources Recommend Favorite

Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model

By Nehete P.N.   Chitta S.   Hossain M.M.   Hill L.   Bernacky B.J.   Baze W.   Arlinghaus R.B.   Sastry K.J.  

Vaccine, Vol. 20, Iss. 5, 2001-12 ,pp. : 813-825

Elsevier

Access to resources Recommend Favorite

Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application

By Caputo A.   Betti M.   Altavilla G.   Bonaccorsi A.   Boarini C.   Marchisio M.   Butto S.   Sparnacci K.   Laus M.   Tondelli L.   Ensoli B.  

Vaccine, Vol. 20, Iss. 17, 2002-05 ,pp. : 2303-2317

Elsevier

Access to resources Recommend Favorite